Enterprise Financial Services Corp Genmab A/S Transaction History

Enterprise Financial Services Corp

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$41.55 - $48.72 $27,007 - $31,668	-650 Closed	0 $0
Q1 2021 May 13, 2021	BUY	$30.92 - $44.4 $3,710 - $5,328	120 Added 22.64%	650 $21,000
Q4 2020 Feb 12, 2021	SELL	$33.66 - $40.76 $1,009 - $1,222	-30 Reduced 5.36%	530 $22,000
Q3 2020 Nov 13, 2020	BUY	$33.07 - $38.68 $5,621 - $6,575	170 Added 43.59%	560 $21,000
Q2 2020 Aug 04, 2020	SELL	$20.05 - $33.89 $802 - $1,355	-40 Reduced 9.3%	390 $13,000
Q1 2020 May 15, 2020	BUY	$17.15 - $25.22 $1,372 - $2,017	80 Added 22.86%	430 $9,000
Q4 2019 Jan 28, 2020	BUY	$18.88 - $24.14 $566 - $724	30 Added 9.38%	350 $8,000
Q3 2019 Oct 31, 2019	BUY	$18.0 - $21.38 $5,760 - $6,841	320 New	320 $6,000

236

52.5M

10.2K

25.5K

Ticker GMAB
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 658,292,992
Market Cap $13.6B
Description
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...

Get notified when there are updates to the investment portfolio of Enterprise Financial Services Corp, based on Form 13F filings with the SEC.

Stay updated on Enterprise Financial Services Corp with notifications on news.